Acquiring Company
Novartis
Acquired Company
Anthos Therapeutics
Switzerland
CambridgeBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth CareTherapeuticsDescription
Novartis has completed its acquisition of Anthos Therapeutics in a deal valued at up to $3.1 billion. Anthos shareholders will receive an upfront payment of $925 million, with additional payments contingent on achieving certain milestones. This acquisition enhances Novartis' portfolio in the field of innovative therapies for cardiometabolic diseases.
Quick answer
Novartis is acquiring Anthos Therapeutics, announced April 4, 2025. Novartis is based in Switzerland.
- How much did Novartis pay for Anthos Therapeutics?
- The deal value was not disclosed.
- What does Novartis do?
- Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel.
- Where are Novartis and Anthos Therapeutics based?
- Novartis is based in Switzerland. Anthos Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Novartis?
- Fundz holds 1 contact at Novartis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in pharmaceuticals and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- Novartis acquires Anthos Therapeutics for $3.1B, $3.1B (April 3, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- Lupin acquires UK-based Renascience Pharma (April 3, 2025)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
- The Lockwood Group acquires IDEOlogy Health (May 12, 2025)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Anthos Therapeutics?
Anthos Therapeutics was acquired by Novartis, based in Switzerland. The deal was reported on April 4, 2025. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire Anthos Therapeutics?
Novartis's acquisition of Anthos Therapeutics was reported on April 4, 2025. Novartis has completed its acquisition of Anthos Therapeutics in a deal valued at up to $3.1 billion. Anthos shareholders will receive an upfront payment of $925 million, with additional payments contingent on achieving certain milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Anthos Therapeutics do?
Anthos Therapeutics, Inc. (Anthos) is a clinical-stage company developing innovative therapies for cardiovascular diseases. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.